ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 2177

Familial Clustering of Systemic Sclerosis, Autoimmunity, and Cancer History

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 1720

FASlpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1966

Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: L13

Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block

(L07–L17) Late-Breaking Abstract Poster

1:00PM-3:00PM: Abstract Number: 2019

Fine Mapping of the Sjögren’s Disease and Systemic Lupus Erythematosus DDX6-CXCR5 Risk Interval Reveals Common SNPs with Functional Significance in Immune and Salivary Gland Cells

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: L12

First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background

(L07–L17) Late-Breaking Abstract Poster

1:00PM-3:00PM: Abstract Number: 2018

Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1946

Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 1810

Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1956

Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1784

Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1920

Gait and Physical Activity Predictors of Knee Replacement: A Machine Learning Analysis in the Multicenter Osteoarthritis Study

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 2159

Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 1940

Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 1892

Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial

Osteoarthritis – Clinical Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].